Pluristem Therapeutics (PSTI) 3.47 $PSTI
Pluristem to Present at World Stem Cells Regenerative Medicine Congress 2014 in London
GlobeNewswire - Mon May 12, 2:00AM CDT
Pluristem Therapeutics, Inc. (Nasdaq
STI) (TASE LTR), a leading developer of placenta-based cell therapies, announced today that the Company's CEO Zami Aberman will participate in the 9 Annual World Stem Cells Regenerative Medicine Congress 2014 in London on May 20 through 22, 2014.
Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) - Pipeline Review, H1 2014: 25 Company and 43 Drug Profiled
M2 - Wed May 07, 9:44AM CDT
Research and Markets (http://www.researchandmarkets.com/research/pjhgmf/radiation) has announced the addition of the "Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) and special features on late-stage and discontinued projects. The report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. Companies Involved: - ActoKine Therapeutics - Aeolus Pharmaceuticals, Inc. - Biothera, Inc. - Bolder Biotechnology, Inc. - CEL-SCI Corporation - Cellerant Therapeutics, Inc. - Cleveland BioLabs, Inc. - Galera Therapeutics LLC - Gamida Cell Ltd. - HEYL Chemisch-pharmazeutische Fabrik GmbH und Co. KG - Humanetics Corporation - ImmuneRegen BioSciences, Inc. - Meabco A/S - Midway Pharmaceuticals, Inc. - Nanotherapeutics, Inc. - NeoStem, Inc. - Neumedicines Inc. - Onconova Therapeutics, Inc. - Osiris Therapeutics, Inc. - Pluristem Therapeutics Inc. - ProCertus BioPharm Inc. - RxBio, Inc. - Soligenix, Inc. - Stealth Peptides Inc. - Terapio Corporation Drug Profiles: - remestemcel-L - entolimod - minocycline - NMIL-121 - BIO-300 - SGX-201 - GC-003 - Leukocyte Interleukin Injection - recilisib sodium - GC-4403 - NanoDTPA - SGX-202 - Homspera - rusalatide acetate - BP-C2 - romyelocel L - MTP-131 - BBT-045 - MDY-1001 - Radiogardase (Prussian Blue insoluble capsules) - JP4-039 - PLX-BMP - GC-4419 - Rx-100 - Stem Cell Therapy For Radiation Exposure - BIO-700 - BIO-800 - CLT-009 - PrC-210 - SY-303A For more information visit http://www.researchandmarkets.com/research/pjhgmf/radiation
Pluristem to be Added to New TA Tech-Elite Stock Index in Israel
GlobeNewswire - Wed May 07, 4:11AM CDT
Pluristem Therapeutics Inc. (Nasdaq STI) (TASE LTR) today announced that its shares of common stock will be added to a newly created TA Tech-Elite index on the Tel Aviv Stock Exchange. Scheduled for launch on May 11, 2014, the TA Tech-Elite index will comprise shares of Israel's leading technology and biomed companies. Initially, the index will include 34 eligible companies with Pluristem comprising approximately 2.05% of the index. The cumulative float-adjusted market cap of these companies exceeds approximately NIS 45 billion ($13 billion). Pluristem's shares of common stock are also currently traded on additional indices such as the Tel Aviv Stock Exchange's TA-100 and TA-75.
Stem Cell Therapy Market by Treatment Mode (Autologous & Allogeneic), Therapeutic Applications (CNS, CVS, GIT, Wound Healing, Musculoskeletal, Eye, & Immune System) - Global Forecasts to 2020
M2 - Tue May 06, 10:27AM CDT
Research and Markets (http://www.researchandmarkets.com/research/wwnrd5/stem_cell_therapy) has announced the addition of the "Stem Cell Therapy Market by Treatment Mode (Autologous & Allogeneic), Therapeutic Applications (CNS, CVS, GIT, Wound Healing, Musculoskeletal, Eye, & Immune System) - Regulatory Landscape, Pipeline Analysis & Global Forecasts to 2020" report to their offering. The global stem cell therapy market on the basis of the mode of treatment is segmented into allogeneic and autologous stem cell therapy. The allogeneic stem cell therapy is expected to command the largest share of the market in 2015, and is also expected to grow at a higher CAGR than autologous therapies from 2015 to 2020. Based on the therapeutic applications, the global market is segmented into eye diseases, metabolic diseases, GIT diseases, musculoskeletal disorders, immune system diseases, CNS diseases, CVS diseases, wounds and injuries, and others. A number of factors such as increasing funding from government and private organizations, growing industry focus on stem cell research, and increasing global awareness about stem cell therapies through various organizations are driving the growth of the global market. Furthermore, increasing funding for new stem cell lines, development of advanced genomic methods for stem cell analysis, and rising approvals of clinical trials for stem cells therapy are other factors that are propelling the growth of the market. Key Topics Covered: 1 INTRODUCTION 2 EXECUTIVE SUMMARY 3 MARKET DYNAMICS 4 PIPELINE ANALYSIS 5 INVESTOR NETWORK 6 GLOBAL STEM CELL THERAPY MARKET, BY MODE OF THERAPY 7 GLOBAL STEM CELL THERAPY MARKET, BY THERAPEUTIC APPLICATIONS 8 REGULATORY LANDSCAPE 9 GLOBAL STEM CELL THERAPY MARKET, BY GEOGRAPHY 10 COMPETITIVE LANDSCAPE 11 COMPANY PROFILES Companies Mentioned: - Aastrom Biosciences Inc. - Advanced Cell Technologies, Inc. - Athersys Inc. - Celgene Corporation - Cellular Dynamics International - Cytori Therapeutics, Inc. - Fibrocell Science, Inc. - Gamida Cell Ltd. - Mesoblast Ltd. - Pluristem Therapeutics Inc. - StemCells Inc. For more information visit http://www.researchandmarkets.com/research/ww...ll_therapy
Pluristem expects USD4.2m grant from OCS' Israeli Government
M2 - Wed Apr 30, 5:03AM CDT
Developer of placenta-based cell therapies Pluristem Therapeutics (NasdaqCM STI) (TASE LTR) said on Wednesday that it expects USD4.2m in grant following authorisation of approval from the Office of the Chief Scientist (OCS) within the Israeli Ministry of Economy.
Pluristem Awarded $4.2 Million Grant by Israeli Government
GlobeNewswire - Wed Apr 30, 2:00AM CDT
Pluristem Therapeutics Inc. (Nasdaq STI) (TASE LTR) today announced that its wholly owned subsidiary, Pluristem Ltd., has received approval for a 14.6 million New Israeli Shekel (approximately $4.2 million) grant from the Office of the Chief Scientist (OCS) within the Israeli Ministry of Economy. Once received, the grant will be used to cover R&D expenses for the period January 2014 to December 2014.
Global Bone Marrow Transplantation Therapeutic Pipeline Review
M2 - Mon Apr 28, 11:58AM CDT
Research and Markets (http://www.researchandmarkets.com/research/lrc2d3/bone_marrow) has announced the addition of the "Bone Marrow Transplantation - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Bone Marrow Transplantation, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Bone Marrow Transplantation and special features on late-stage and discontinued projects. Companies Involved in Therapeutics Development - Mesoblast Limited - Cleveland BioLabs, Inc. - Compugen Ltd. - Pluristem Therapeutics Inc. - Spectrum Pharmaceuticals, Inc. - TikoMed AB - Taiga Biotechnologies, Inc. Drug Profiles - Allogeneic MPC For Bone Marrow Transplantation - melphalan - TM-400 - PLX-BMP - CBLB-612 - CBLB-612 - CGEN-15001 - Small Molecule to Inhibit Perforin for Bone Marrow Transplantation - Protein for Bone Marrow Transplantation Companies Mentioned: - Mesoblast Limited - Cleveland BioLabs, Inc. - Compugen Ltd. - Pluristem Therapeutics Inc. - Spectrum Pharmaceuticals, Inc. - TikoMed AB - Taiga Biotechnologies, Inc. For more information visit http://www.researchandmarkets.com/research/lr...one_marrow
Pluristem Therapeutics' manufacturing facility approved for Phase III trials upon European Auditors' authorisation
M2 - Mon Apr 28, 5:39AM CDT
Cell therapies company Pluristem Therapeutics (NasdaqCM STI) (TASE LTR) disclosed on Monday that its new manufacturing facility has passed the EU's Qualified Person Declaration.
Pluristem's Manufacturing Facility Approved by European Auditors for Phase III Trials
GlobeNewswire - Mon Apr 28, 2:00AM CDT
Pluristem Therapeutics Inc. (Nasdaq STI) (TASE LTR) today announced that its new manufacturing facility has received the European Union's Qualified Person Declaration. With this declaration, Pluristem is now approved to use cell therapies manufactured at its state-of-the-art facility located in Haifa, Israel, in all phases of its clinical trials conducted in the European Union, including Phase I, Phase II and Phase III.
Pluristem and the Alliance for Regenerative Medicine Advocate for Industry Advancement in Washington D.C.
GlobeNewswire - Tue Apr 22, 2:00AM CDT
Pluristem Therapeutics, Inc. (Nasdaq STI) (TASE LTR), a leading developer of placenta-based cell therapies, announced today that Company executives are actively participating in a series of meetings in Washington D.C. regarding proposed legislation that may impact the future of cell therapy and regenerative medicine in the U.S.
Pluristem to Deliver Key Commercialization and Scientific Presentations at International Society for Cellular Therapy Conference 2014
GlobeNewswire - Wed Apr 16, 2:00AM CDT
Pluristem Therapeutics, Inc. (Nasdaq STI) (TASE LTR), a leading developer of placenta-based cell therapies, announced today that Dr. Ohad Karnieli, Vice President of Development and Manufacturing, and Lena Pinzur, Basic and Preclinical Research Manager, will deliver presentations at the International Society for Cellular Therapy (ISCT) 2014 Conference which will take place in Paris, France on April 23 through 26, 2014. Additionally, Racheli Ofir, Vice President of Research & IP will be participating in ISCT's Industry Education Subcommittee. The ISCT is a global society of clinicians, regulators, technologists, and industry partners with a shared vision to translate cellular therapy into safe and effective treatments to improve patients' lives. Pluristem supports the advancement of cell therapy not only through its breakthrough technologies, but also through active participation in industry organizations like ISCT that play a key role in shaping the future of the industry.
UK's Minister for Universities and Science, David Willetts & His Delegation Visit Pluristem Regarding UK-Israel Cooperation on Regenerative Medicine
GlobeNewswire - Wed Mar 26, 3:00AM CDT
Pluristem Therapeutics, Inc. (Nasdaq STI) (TASE LTR), a leading developer of placenta-based cell therapies, announced today that a delegation from the UK made an official visit to Pluristem on March 25, 2014. Officials visiting Pluristem included the UK's Minister for Universities and Science, David Willetts, whose responsibilities include overseeing the Department of Business Innovation and Skills (BIS), and Dr. Stephen Ward, Chief Operating Officer of the Cell Therapy Catapult, a non-profit organization which aims to grow the UK cell therapy industry.
Pluristem Scientists to Present a Poster on GvHD & Participate in a Panel Discussion at the BIRAX Regenerative Medicine Conference
GlobeNewswire - Tue Mar 25, 3:00AM CDT
Pluristem Therapeutics, Inc. (Nasdaq STI) (TASE LTR), a leading developer of placenta-based cell therapies, today announced its participation in the 2nd UK-Israel Regenerative Medicine Conference (BIRAX), which is being held on March 25 and 26, 2014 in Haifa at the Ruth and Bruce Rappaport Faculty of Medicine, Technion - Israel Institute of Technology.
Preclinical Results for Pluristem's PLX-PAD Cells in Tendon Injury Presented at American Academy of Orthopedic Surgeons' Annual Meeting
GlobeNewswire - Wed Mar 12, 3:00AM CDT
Pluristem Therapeutics, Inc. (Nasdaq STI) (TASE LTR), a leading developer of placenta-based cell therapies, today announced that Dr. Scott Rodeo of New York's Hospital for Special Surgery (HSS) presented his research findings in a scientific poster titled, "Use of Human Placental-Derived Adherent Stromal Cells Improves Tendon Healing in a Preclinical Model of Tendon Injury," at the American Academy of Orthopedic Surgeons' (AAOS) Annual Meeting, on March 11-15 in New Orleans.
Appointments, Financial Reports, and FDA Approvals - Analyst Notes on Hospira, Karyopharm, Revance, Pluristem, and Sunesis
PR Newswire - Tue Mar 11, 8:19AM CDT
Today, Analysts Review released its analysts' notes regarding Hospira Inc. (NYSE: HSP), Karyopharm Therapeutics, Inc. (NASDAQ: KPTI), Revance Therapeutics, Inc. (NASDAQ: RVNC), Pluristem Therapeutics, Inc. (NASDAQ: PSTI), and Sunesis Pharmaceuticals, Inc. (NASDAQ: SNSS). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.AnalystsReview.com/register
Pluristem to Present at Barclays and RegenMed Financial Conferences
GlobeNewswire - Tue Mar 11, 2:59AM CDT
Pluristem Therapeutics, Inc. (Nasdaq STI) (TASE LTR), a leading developer of placenta-based cell therapies, today announced that Company executives will present at two upcoming financial conferences:
Global Stem Cell Umbilical Cord Blood (UCB) Market to 2020
M2 - Mon Mar 10, 7:45AM CDT
Research and Markets (http://www.researchandmarkets.com/research/gsw6jj/global_stem_cell) has announced the addition of the "Global Stem Cell Umbilical Cord Blood (UCB) Market to 2020" report to their offering. The market is expected to reach revenue of $56.4 billion by 2020, growing at CAGR of 33.4% during 2013 to 2020 The study observed that the global umbilical cord blood stem cell market is forecasted to reach market value over $11.5 billion in 2014 from $ 6.5 billion in 2012. Developments and approvals for novel cord blood stem cells therapies is expected to drive the market growth. The storage service market was valued at $7.4 billion in 2013. Increase in prevalence rate of chronic diseases such as cancer, diabetes, blood disease, immune disease, metabolic disease etc. has increased the need of cost effective and efficient way of treatment. However, cord blood stem cells have the potential to treat these chronic diseases effectively. These stem cells have special property of higher cell count in lower blood volume. Collection of these stem cells is much easier than other stem cells and could be stored in specialized preservation facilities called as Cord Blood Stem Cell Banks.Cord blood stem cells market is in its emerging phase. Significant applications of stem cells in the treatment of various disorders will be commercialized very soon as most of them are in the last phase of clinical trials. Patents for collection techniques and therapeutics methods are approved by respective government of developed countries however patents for UCB stem cells are comparatively less in developing economies. According to lead analyst Debbie Shields, the geographic analysis shows that the North American market for cord blood stem cell would account for approx. 44% of total revenue generated by the cord blood market in 2013. However, much expected growth is to occur in Asia-Pacific regions during the forecast period, because of growing demand for chronic disease treatments and widely increasing awareness levels. This report study offers updated review about major market players present in this market such as researcher based pharmaceutical companies and therapeutics services companies. Key Market Segments Global Stem cell UCB market by storage - Public cord blood banks - Private cord blood banks - Public Vs. Private UCB banks Global Stem cell UCB market by Diseases - Cancer/ Oncology diseases - Acute Leukemia - Chronic Leukemia - High Risk Solid Tumors - Myelodysplastic Syndrome - Blood diseases - Aplastic Anemia - Beta Thalassemia - Sickle Cell disease - Immune Disorders - Leukocyte Adhesion Deficiency - Hystiocytic Disorders - Wiskott-Aldrich - Metabolic Disorders - Krabbe Disease - Hurler Syndrome - Sanfilippo Syndrome - Other diseases - Osteopetrosis - Hemophagoyticlymphohistiocytosis Global Stem cell UCB market by Technology - Stem Cell Transplant - Autologous transplant - Allogenic transplant - Transplant Medicine - Regenerative Medicine - Others - Cord Blood Banking - Blood Transfusion - Cell Based Genetics Companies Mentioned - Advanced Cell Technology Inc. (USA) - Athersys Inc. - California Stem Cell - Cytori Therapeutics Inc. - Geron Corporation - Mesoblast Limited - NeoStem Inc. - Opexa Therapeutics Inc. - Osiris Therapeutics - Pluristem Therapeutics Inc. For more information visit http://www.researchandmarkets.com/research/gs..._stem_cell
Pluristem CEO Zami Aberman to Present on Cell & Gene Therapy Panel Discussion at BIO-Europe Spring 2014
GlobeNewswire - Fri Mar 07, 9:45AM CST
Pluristem Therapeutics, Inc. (Nasdaq STI) (TASE LTR), a leading developer of placenta-based cell therapies, today announced the Company's Chief Executive Officer Zami Aberman will deliver a brief presentation and be a panelist at BIO-Europe Spring 2014 on March 10, 2014 at 4pm. BIO-Europe Spring 2014 will take place on March 10-12 in Turin, Italy.
Top Stories in Biotech This Morning: Pluristem Therapeutics, Inc, Rigel Pharmaceuticals, Inc. and Sa
George Budwell, The Motley Fool - Motley Fool - Thu Mar 06, 7:49AM CST
Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis. Let's take a look at the top stories in biotech and health...
US FDA Approves Pluristem's Commercial Scale Cell Manufacturing Process
GlobeNewswire - Thu Mar 06, 2:00AM CST
Pluristem Therapeutics, Inc. (Nasdaq STI) (TASE LTR), a leading developer of placenta-based cell therapies, today announced that the United States Food and Drug Administration (FDA) has reviewed Pluristem's comparability studies of its PLacental eXpanded (PLX) cell products and granted approval for the Company to manufacture these products in its new commercial-scale cell manufacturing facility.
Pluristem to Present at World Stem Cells Regenerative Medicine Congress 2014 in London
GlobeNewswire - Mon May 12, 2:00AM CDT
Pluristem Therapeutics, Inc. (Nasdaq
STI) (TASE LTR), a leading developer of placenta-based cell therapies, announced today that the Company's CEO Zami Aberman will participate in the 9 Annual World Stem Cells Regenerative Medicine Congress 2014 in London on May 20 through 22, 2014. Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) - Pipeline Review, H1 2014: 25 Company and 43 Drug Profiled
M2 - Wed May 07, 9:44AM CDT
Research and Markets (http://www.researchandmarkets.com/research/pjhgmf/radiation) has announced the addition of the "Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) and special features on late-stage and discontinued projects. The report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. Companies Involved: - ActoKine Therapeutics - Aeolus Pharmaceuticals, Inc. - Biothera, Inc. - Bolder Biotechnology, Inc. - CEL-SCI Corporation - Cellerant Therapeutics, Inc. - Cleveland BioLabs, Inc. - Galera Therapeutics LLC - Gamida Cell Ltd. - HEYL Chemisch-pharmazeutische Fabrik GmbH und Co. KG - Humanetics Corporation - ImmuneRegen BioSciences, Inc. - Meabco A/S - Midway Pharmaceuticals, Inc. - Nanotherapeutics, Inc. - NeoStem, Inc. - Neumedicines Inc. - Onconova Therapeutics, Inc. - Osiris Therapeutics, Inc. - Pluristem Therapeutics Inc. - ProCertus BioPharm Inc. - RxBio, Inc. - Soligenix, Inc. - Stealth Peptides Inc. - Terapio Corporation Drug Profiles: - remestemcel-L - entolimod - minocycline - NMIL-121 - BIO-300 - SGX-201 - GC-003 - Leukocyte Interleukin Injection - recilisib sodium - GC-4403 - NanoDTPA - SGX-202 - Homspera - rusalatide acetate - BP-C2 - romyelocel L - MTP-131 - BBT-045 - MDY-1001 - Radiogardase (Prussian Blue insoluble capsules) - JP4-039 - PLX-BMP - GC-4419 - Rx-100 - Stem Cell Therapy For Radiation Exposure - BIO-700 - BIO-800 - CLT-009 - PrC-210 - SY-303A For more information visit http://www.researchandmarkets.com/research/pjhgmf/radiation
Pluristem to be Added to New TA Tech-Elite Stock Index in Israel
GlobeNewswire - Wed May 07, 4:11AM CDT
Pluristem Therapeutics Inc. (Nasdaq
STI) (TASE LTR) today announced that its shares of common stock will be added to a newly created TA Tech-Elite index on the Tel Aviv Stock Exchange. Scheduled for launch on May 11, 2014, the TA Tech-Elite index will comprise shares of Israel's leading technology and biomed companies. Initially, the index will include 34 eligible companies with Pluristem comprising approximately 2.05% of the index. The cumulative float-adjusted market cap of these companies exceeds approximately NIS 45 billion ($13 billion). Pluristem's shares of common stock are also currently traded on additional indices such as the Tel Aviv Stock Exchange's TA-100 and TA-75. Stem Cell Therapy Market by Treatment Mode (Autologous & Allogeneic), Therapeutic Applications (CNS, CVS, GIT, Wound Healing, Musculoskeletal, Eye, & Immune System) - Global Forecasts to 2020
M2 - Tue May 06, 10:27AM CDT
Research and Markets (http://www.researchandmarkets.com/research/wwnrd5/stem_cell_therapy) has announced the addition of the "Stem Cell Therapy Market by Treatment Mode (Autologous & Allogeneic), Therapeutic Applications (CNS, CVS, GIT, Wound Healing, Musculoskeletal, Eye, & Immune System) - Regulatory Landscape, Pipeline Analysis & Global Forecasts to 2020" report to their offering. The global stem cell therapy market on the basis of the mode of treatment is segmented into allogeneic and autologous stem cell therapy. The allogeneic stem cell therapy is expected to command the largest share of the market in 2015, and is also expected to grow at a higher CAGR than autologous therapies from 2015 to 2020. Based on the therapeutic applications, the global market is segmented into eye diseases, metabolic diseases, GIT diseases, musculoskeletal disorders, immune system diseases, CNS diseases, CVS diseases, wounds and injuries, and others. A number of factors such as increasing funding from government and private organizations, growing industry focus on stem cell research, and increasing global awareness about stem cell therapies through various organizations are driving the growth of the global market. Furthermore, increasing funding for new stem cell lines, development of advanced genomic methods for stem cell analysis, and rising approvals of clinical trials for stem cells therapy are other factors that are propelling the growth of the market. Key Topics Covered: 1 INTRODUCTION 2 EXECUTIVE SUMMARY 3 MARKET DYNAMICS 4 PIPELINE ANALYSIS 5 INVESTOR NETWORK 6 GLOBAL STEM CELL THERAPY MARKET, BY MODE OF THERAPY 7 GLOBAL STEM CELL THERAPY MARKET, BY THERAPEUTIC APPLICATIONS 8 REGULATORY LANDSCAPE 9 GLOBAL STEM CELL THERAPY MARKET, BY GEOGRAPHY 10 COMPETITIVE LANDSCAPE 11 COMPANY PROFILES Companies Mentioned: - Aastrom Biosciences Inc. - Advanced Cell Technologies, Inc. - Athersys Inc. - Celgene Corporation - Cellular Dynamics International - Cytori Therapeutics, Inc. - Fibrocell Science, Inc. - Gamida Cell Ltd. - Mesoblast Ltd. - Pluristem Therapeutics Inc. - StemCells Inc. For more information visit http://www.researchandmarkets.com/research/ww...ll_therapy
Pluristem expects USD4.2m grant from OCS' Israeli Government
M2 - Wed Apr 30, 5:03AM CDT
Developer of placenta-based cell therapies Pluristem Therapeutics (NasdaqCM
STI) (TASE LTR) said on Wednesday that it expects USD4.2m in grant following authorisation of approval from the Office of the Chief Scientist (OCS) within the Israeli Ministry of Economy. Pluristem Awarded $4.2 Million Grant by Israeli Government
GlobeNewswire - Wed Apr 30, 2:00AM CDT
Pluristem Therapeutics Inc. (Nasdaq
STI) (TASE LTR) today announced that its wholly owned subsidiary, Pluristem Ltd., has received approval for a 14.6 million New Israeli Shekel (approximately $4.2 million) grant from the Office of the Chief Scientist (OCS) within the Israeli Ministry of Economy. Once received, the grant will be used to cover R&D expenses for the period January 2014 to December 2014. Global Bone Marrow Transplantation Therapeutic Pipeline Review
M2 - Mon Apr 28, 11:58AM CDT
Research and Markets (http://www.researchandmarkets.com/research/lrc2d3/bone_marrow) has announced the addition of the "Bone Marrow Transplantation - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Bone Marrow Transplantation, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Bone Marrow Transplantation and special features on late-stage and discontinued projects. Companies Involved in Therapeutics Development - Mesoblast Limited - Cleveland BioLabs, Inc. - Compugen Ltd. - Pluristem Therapeutics Inc. - Spectrum Pharmaceuticals, Inc. - TikoMed AB - Taiga Biotechnologies, Inc. Drug Profiles - Allogeneic MPC For Bone Marrow Transplantation - melphalan - TM-400 - PLX-BMP - CBLB-612 - CBLB-612 - CGEN-15001 - Small Molecule to Inhibit Perforin for Bone Marrow Transplantation - Protein for Bone Marrow Transplantation Companies Mentioned: - Mesoblast Limited - Cleveland BioLabs, Inc. - Compugen Ltd. - Pluristem Therapeutics Inc. - Spectrum Pharmaceuticals, Inc. - TikoMed AB - Taiga Biotechnologies, Inc. For more information visit http://www.researchandmarkets.com/research/lr...one_marrow
Pluristem Therapeutics' manufacturing facility approved for Phase III trials upon European Auditors' authorisation
M2 - Mon Apr 28, 5:39AM CDT
Cell therapies company Pluristem Therapeutics (NasdaqCM
STI) (TASE LTR) disclosed on Monday that its new manufacturing facility has passed the EU's Qualified Person Declaration. Pluristem's Manufacturing Facility Approved by European Auditors for Phase III Trials
GlobeNewswire - Mon Apr 28, 2:00AM CDT
Pluristem Therapeutics Inc. (Nasdaq
STI) (TASE LTR) today announced that its new manufacturing facility has received the European Union's Qualified Person Declaration. With this declaration, Pluristem is now approved to use cell therapies manufactured at its state-of-the-art facility located in Haifa, Israel, in all phases of its clinical trials conducted in the European Union, including Phase I, Phase II and Phase III. Pluristem and the Alliance for Regenerative Medicine Advocate for Industry Advancement in Washington D.C.
GlobeNewswire - Tue Apr 22, 2:00AM CDT
Pluristem Therapeutics, Inc. (Nasdaq
STI) (TASE LTR), a leading developer of placenta-based cell therapies, announced today that Company executives are actively participating in a series of meetings in Washington D.C. regarding proposed legislation that may impact the future of cell therapy and regenerative medicine in the U.S. Pluristem to Deliver Key Commercialization and Scientific Presentations at International Society for Cellular Therapy Conference 2014
GlobeNewswire - Wed Apr 16, 2:00AM CDT
Pluristem Therapeutics, Inc. (Nasdaq
STI) (TASE LTR), a leading developer of placenta-based cell therapies, announced today that Dr. Ohad Karnieli, Vice President of Development and Manufacturing, and Lena Pinzur, Basic and Preclinical Research Manager, will deliver presentations at the International Society for Cellular Therapy (ISCT) 2014 Conference which will take place in Paris, France on April 23 through 26, 2014. Additionally, Racheli Ofir, Vice President of Research & IP will be participating in ISCT's Industry Education Subcommittee. The ISCT is a global society of clinicians, regulators, technologists, and industry partners with a shared vision to translate cellular therapy into safe and effective treatments to improve patients' lives. Pluristem supports the advancement of cell therapy not only through its breakthrough technologies, but also through active participation in industry organizations like ISCT that play a key role in shaping the future of the industry. UK's Minister for Universities and Science, David Willetts & His Delegation Visit Pluristem Regarding UK-Israel Cooperation on Regenerative Medicine
GlobeNewswire - Wed Mar 26, 3:00AM CDT
Pluristem Therapeutics, Inc. (Nasdaq
STI) (TASE LTR), a leading developer of placenta-based cell therapies, announced today that a delegation from the UK made an official visit to Pluristem on March 25, 2014. Officials visiting Pluristem included the UK's Minister for Universities and Science, David Willetts, whose responsibilities include overseeing the Department of Business Innovation and Skills (BIS), and Dr. Stephen Ward, Chief Operating Officer of the Cell Therapy Catapult, a non-profit organization which aims to grow the UK cell therapy industry. Pluristem Scientists to Present a Poster on GvHD & Participate in a Panel Discussion at the BIRAX Regenerative Medicine Conference
GlobeNewswire - Tue Mar 25, 3:00AM CDT
Pluristem Therapeutics, Inc. (Nasdaq
STI) (TASE LTR), a leading developer of placenta-based cell therapies, today announced its participation in the 2nd UK-Israel Regenerative Medicine Conference (BIRAX), which is being held on March 25 and 26, 2014 in Haifa at the Ruth and Bruce Rappaport Faculty of Medicine, Technion - Israel Institute of Technology. Preclinical Results for Pluristem's PLX-PAD Cells in Tendon Injury Presented at American Academy of Orthopedic Surgeons' Annual Meeting
GlobeNewswire - Wed Mar 12, 3:00AM CDT
Pluristem Therapeutics, Inc. (Nasdaq
STI) (TASE LTR), a leading developer of placenta-based cell therapies, today announced that Dr. Scott Rodeo of New York's Hospital for Special Surgery (HSS) presented his research findings in a scientific poster titled, "Use of Human Placental-Derived Adherent Stromal Cells Improves Tendon Healing in a Preclinical Model of Tendon Injury," at the American Academy of Orthopedic Surgeons' (AAOS) Annual Meeting, on March 11-15 in New Orleans. Appointments, Financial Reports, and FDA Approvals - Analyst Notes on Hospira, Karyopharm, Revance, Pluristem, and Sunesis
PR Newswire - Tue Mar 11, 8:19AM CDT
Today, Analysts Review released its analysts' notes regarding Hospira Inc. (NYSE: HSP), Karyopharm Therapeutics, Inc. (NASDAQ: KPTI), Revance Therapeutics, Inc. (NASDAQ: RVNC), Pluristem Therapeutics, Inc. (NASDAQ: PSTI), and Sunesis Pharmaceuticals, Inc. (NASDAQ: SNSS). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.AnalystsReview.com/register
Pluristem to Present at Barclays and RegenMed Financial Conferences
GlobeNewswire - Tue Mar 11, 2:59AM CDT
Pluristem Therapeutics, Inc. (Nasdaq
STI) (TASE LTR), a leading developer of placenta-based cell therapies, today announced that Company executives will present at two upcoming financial conferences: Global Stem Cell Umbilical Cord Blood (UCB) Market to 2020
M2 - Mon Mar 10, 7:45AM CDT
Research and Markets (http://www.researchandmarkets.com/research/gsw6jj/global_stem_cell) has announced the addition of the "Global Stem Cell Umbilical Cord Blood (UCB) Market to 2020" report to their offering. The market is expected to reach revenue of $56.4 billion by 2020, growing at CAGR of 33.4% during 2013 to 2020 The study observed that the global umbilical cord blood stem cell market is forecasted to reach market value over $11.5 billion in 2014 from $ 6.5 billion in 2012. Developments and approvals for novel cord blood stem cells therapies is expected to drive the market growth. The storage service market was valued at $7.4 billion in 2013. Increase in prevalence rate of chronic diseases such as cancer, diabetes, blood disease, immune disease, metabolic disease etc. has increased the need of cost effective and efficient way of treatment. However, cord blood stem cells have the potential to treat these chronic diseases effectively. These stem cells have special property of higher cell count in lower blood volume. Collection of these stem cells is much easier than other stem cells and could be stored in specialized preservation facilities called as Cord Blood Stem Cell Banks.Cord blood stem cells market is in its emerging phase. Significant applications of stem cells in the treatment of various disorders will be commercialized very soon as most of them are in the last phase of clinical trials. Patents for collection techniques and therapeutics methods are approved by respective government of developed countries however patents for UCB stem cells are comparatively less in developing economies. According to lead analyst Debbie Shields, the geographic analysis shows that the North American market for cord blood stem cell would account for approx. 44% of total revenue generated by the cord blood market in 2013. However, much expected growth is to occur in Asia-Pacific regions during the forecast period, because of growing demand for chronic disease treatments and widely increasing awareness levels. This report study offers updated review about major market players present in this market such as researcher based pharmaceutical companies and therapeutics services companies. Key Market Segments Global Stem cell UCB market by storage - Public cord blood banks - Private cord blood banks - Public Vs. Private UCB banks Global Stem cell UCB market by Diseases - Cancer/ Oncology diseases - Acute Leukemia - Chronic Leukemia - High Risk Solid Tumors - Myelodysplastic Syndrome - Blood diseases - Aplastic Anemia - Beta Thalassemia - Sickle Cell disease - Immune Disorders - Leukocyte Adhesion Deficiency - Hystiocytic Disorders - Wiskott-Aldrich - Metabolic Disorders - Krabbe Disease - Hurler Syndrome - Sanfilippo Syndrome - Other diseases - Osteopetrosis - Hemophagoyticlymphohistiocytosis Global Stem cell UCB market by Technology - Stem Cell Transplant - Autologous transplant - Allogenic transplant - Transplant Medicine - Regenerative Medicine - Others - Cord Blood Banking - Blood Transfusion - Cell Based Genetics Companies Mentioned - Advanced Cell Technology Inc. (USA) - Athersys Inc. - California Stem Cell - Cytori Therapeutics Inc. - Geron Corporation - Mesoblast Limited - NeoStem Inc. - Opexa Therapeutics Inc. - Osiris Therapeutics - Pluristem Therapeutics Inc. For more information visit http://www.researchandmarkets.com/research/gs..._stem_cell
Pluristem CEO Zami Aberman to Present on Cell & Gene Therapy Panel Discussion at BIO-Europe Spring 2014
GlobeNewswire - Fri Mar 07, 9:45AM CST
Pluristem Therapeutics, Inc. (Nasdaq
STI) (TASE LTR), a leading developer of placenta-based cell therapies, today announced the Company's Chief Executive Officer Zami Aberman will deliver a brief presentation and be a panelist at BIO-Europe Spring 2014 on March 10, 2014 at 4pm. BIO-Europe Spring 2014 will take place on March 10-12 in Turin, Italy. Top Stories in Biotech This Morning: Pluristem Therapeutics, Inc, Rigel Pharmaceuticals, Inc. and Sa
George Budwell, The Motley Fool - Motley Fool - Thu Mar 06, 7:49AM CST
Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis. Let's take a look at the top stories in biotech and health...
US FDA Approves Pluristem's Commercial Scale Cell Manufacturing Process
GlobeNewswire - Thu Mar 06, 2:00AM CST
Pluristem Therapeutics, Inc. (Nasdaq
STI) (TASE LTR), a leading developer of placenta-based cell therapies, today announced that the United States Food and Drug Administration (FDA) has reviewed Pluristem's comparability studies of its PLacental eXpanded (PLX) cell products and granted approval for the Company to manufacture these products in its new commercial-scale cell manufacturing facility. 
